Startups
oncozenge.se
Edit

oncozenge.se

http://oncozenge.se/
Last activity: 23.09.2026
Active
Categories: MedtechProduct
OncoZenge is developing a lozenge that will help millions of people with their oral pain. Our primary indication is oral mucositis, a painful side effect from radiotherapy and chemotherapy.
LinkedInEmail
Mentions
40

Mentions in press and media 40

DateTitleDescription
Sign up to seeSign up to seeSign up to see
Sep 22, 2025OncoZenge AB - Capital Markets Day 2025 On-Demand Video Now AvailableOncoZenge AB - Capital Markets Day 2025 On-Demand Video Now Available Mon, Sep 22, 2025 15:20 CET Report this content OncoZenge AB (publ) (“OncoZenge” or “the Company”), a pharmaceutical company developing an innovative treatment for oral p...
Sep 17, 2025OncoZenge AB Enters into Collaboration with UCLA for Patient Engagement Study on BupiZenge™OncoZenge AB Enters into Collaboration with UCLA for Patient Engagement Study on BupiZenge™ Wed, Sep 17, 2025 08:50 CET Report this content OncoZenge AB (publ) (“OncoZenge” or “the Company”), a pharmaceutical company developing an innovativ...
Sep 10, 2025OncoZenge AB appoints LINK Medical as CRO for BupiZenge™ Phase III executionOncoZenge AB appoints LINK Medical as CRO for BupiZenge™ Phase III execution Wed, Sep 10, 2025 17:10 CET Report this content OncoZenge AB has selected LINK Medical, a Nordic-based clinical research organization (CRO), to lead the Phase III ...
Aug 27, 2025Invitation to OncoZenge's Capital Markets Day on 18 September 2025Invitation to OncoZenge's Capital Markets Day on 18 September 2025 Wed, Aug 27, 2025 16:00 CET Report this content OncoZenge AB (publ), a late-stage pharmaceutical company advancing its lead candidate BupiZenge™ into Phase III execution, is...
Aug 21, 2025OncoZenge AB Interim Report January 1 – June 30, 2025OncoZenge AB Interim Report January 1 – June 30, 2025 Thu, Aug 21, 2025 08:00 CET Report this content OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced the interim report for the second quarter of 2025. ...
Aug 13, 2025OncoZenge Event Calendar September – December 2025OncoZenge Event Calendar September – December 2025 Wed, Aug 13, 2025 11:35 CET Report this content OncoZenge AB (publ) ("OncoZenge" or "the Company") today publishes its event calendar for September to December 2025. Sch...
Aug 13, 2025OncoZenge Changes Reporting Language to EnglishOncoZenge Changes Reporting Language to English Wed, Aug 13, 2025 10:55 CET Report this content OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces the change to English as reporting language in order to m...
Jul 30, 2025OncoZenge Provides Market and Strategy UpdateOncoZenge Provides Market and Strategy Update Wed, Jul 30, 2025 08:50 CET Report this content OncoZenge AB (publ) (“OncoZenge” or “the Company”) today announced a comprehensive market and strategy update after successfully securing full fun...
Jul 21, 2025OncoZenge Appoints Meribel Pharma as CDMO for BupiZenge™ Phase 3 ProjectOncoZenge Appoints Meribel Pharma as CDMO for BupiZenge™ Phase 3 Project Mon, Jul 21, 2025 09:50 CET Report this content OncoZenge AB ("OncoZenge" or "the Company") today announced it has engaged Meribel Pharma Solutions...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In

FAQ about oncozenge.se

What has the press written about oncozenge.se?

Parsers VC has collected 40 articles mentioning oncozenge.se, among them “OncoZenge AB - Capital Markets Day 2025 On-Demand Video Now Available” (Sep 22, 2025) and “OncoZenge AB Enters into Collaboration with UCLA for Patient Engagement Study on BupiZenge™” (Sep 17, 2025).

Is oncozenge.se still active?

Yes, oncozenge.se is active; its latest activity on Parsers VC dates from Sep 23, 2026.